Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Federal Trade Commission
Boehringer Ingelheim
Express Scripts

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,670,537

« Back to Dashboard

Summary for Patent: 5,670,537

Title: Method for effecting tumor regression with a low dose, short infusion taxol regimen
Abstract:Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
Inventor(s): Canetta; Renzo Mauro (Madison, CT), Eisenhauer; Elizabeth (Kingston, CA), Rozencweig; Marcel (Brandford, CT)
Assignee: Bristol-Meyers Squibb Company (Princeton, NJ)
Application Number:08/715,914
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 5,670,537

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2086874► Subscribe
Switzerland686868► Subscribe
Cyprus2049► Subscribe
Germany4325927► Subscribe
Germany69310634► Subscribe
Denmark65293► Subscribe
Denmark0584001► Subscribe
European Patent Office0584001► Subscribe
European Patent Office0783885► Subscribe
European Patent Office0783886► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus